All In Biotech

Drug Trial Radar · NCT01247675

A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency

A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

37

Actual

Start

Nov 2010

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Nov 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth hormone product over a period of 4 weeks (4 weekly administrations versus 28 daily administrations) in adults with Growth Hormone Deficiency.

Conditions

  • Adult Growth Hormone Deficiency

Interventions

  • ACP-001 (TransCon hGH)Drug

    s.c., weekly injection

  • ACP-001 (TransCon hGH)Drug

    s.c., weekly injection

  • ACP-001 (TransCon hGH)Drug

    s.c., weekly injection

  • OmnitropeDrug

    s.c., daily injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator)Time frame: Start of study treatment through Week 4
  2. Incidence of Treatment Emergent Anti-hGH Binding Antibody FormationTime frame: Start of study treatment through Day 42

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus, Denmark

  • Charité University Hospital Berlin

    Berlin, Germany

  • University Hospital Genova

    Genova, Italy

  • Karolinska University Hospital

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.